Sera Prognostics, Inc.
Sera Prognostics, Inc. SERA Peers
See (SERA) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| SERA | $2.77 | -32.27% | 101.7M | -2.95 | -$0.94 | N/A |
| DHR-PB | $1,261.26 | -0.78% | 916.8B | 146.01 | $8.64 | +0.60% |
| TMO | $405.46 | -0.69% | 153B | 23.76 | $17.06 | +0.40% |
| DHR | $197.54 | -0.63% | 141.4B | 38.21 | $5.17 | +0.60% |
| IDXX | $536.34 | +0.94% | 43.1B | 49.62 | $10.81 | N/A |
| A | $118.01 | -0.97% | 33.5B | 29.06 | $4.06 | +0.82% |
| IQV | $157.59 | +0.08% | 27.2B | 21.49 | $7.33 | N/A |
| MTD | $1,174.72 | -0.83% | 24.4B | 29.33 | $40.04 | N/A |
| NTRA | $168.94 | +0.58% | 23.1B | -114.15 | -$1.48 | N/A |
| WAT | $349.04 | -0.96% | 20.8B | 31.64 | $11.03 | N/A |
Stock Comparison
SERA vs DHR-PB Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, SERA is priced at $2.77, while DHR-PB trades at $1,261.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, SERA's ROE is -0.51%, compared to DHR-PB's ROE of +0.07%. Regarding short-term risk, SERA is more volatile compared to DHR-PB. This indicates potentially higher risk in terms of short-term price fluctuations for SERA.
SERA vs TMO Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, TMO has a market cap of 153B. Regarding current trading prices, SERA is priced at $2.77, while TMO trades at $405.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas TMO's P/E ratio is 23.76. In terms of profitability, SERA's ROE is -0.51%, compared to TMO's ROE of +0.13%. Regarding short-term risk, SERA is more volatile compared to TMO. This indicates potentially higher risk in terms of short-term price fluctuations for SERA.
SERA vs DHR Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, DHR has a market cap of 141.4B. Regarding current trading prices, SERA is priced at $2.77, while DHR trades at $197.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas DHR's P/E ratio is 38.21. In terms of profitability, SERA's ROE is -0.51%, compared to DHR's ROE of +0.07%. Regarding short-term risk, SERA is more volatile compared to DHR. This indicates potentially higher risk in terms of short-term price fluctuations for SERA.
SERA vs IDXX Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, IDXX has a market cap of 43.1B. Regarding current trading prices, SERA is priced at $2.77, while IDXX trades at $536.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas IDXX's P/E ratio is 49.62. In terms of profitability, SERA's ROE is -0.51%, compared to IDXX's ROE of +0.57%. Regarding short-term risk, SERA is more volatile compared to IDXX. This indicates potentially higher risk in terms of short-term price fluctuations for SERA.
SERA vs A Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, A has a market cap of 33.5B. Regarding current trading prices, SERA is priced at $2.77, while A trades at $118.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas A's P/E ratio is 29.06. In terms of profitability, SERA's ROE is -0.51%, compared to A's ROE of +0.19%. Regarding short-term risk, SERA is more volatile compared to A. This indicates potentially higher risk in terms of short-term price fluctuations for SERA.
SERA vs IQV Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, IQV has a market cap of 27.2B. Regarding current trading prices, SERA is priced at $2.77, while IQV trades at $157.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas IQV's P/E ratio is 21.49. In terms of profitability, SERA's ROE is -0.51%, compared to IQV's ROE of +0.21%. Regarding short-term risk, SERA is more volatile compared to IQV. This indicates potentially higher risk in terms of short-term price fluctuations for SERA.
SERA vs MTD Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, MTD has a market cap of 24.4B. Regarding current trading prices, SERA is priced at $2.77, while MTD trades at $1,174.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas MTD's P/E ratio is 29.33. In terms of profitability, SERA's ROE is -0.51%, compared to MTD's ROE of +1.21%. Regarding short-term risk, SERA is more volatile compared to MTD. This indicates potentially higher risk in terms of short-term price fluctuations for SERA.
SERA vs NTRA Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, NTRA has a market cap of 23.1B. Regarding current trading prices, SERA is priced at $2.77, while NTRA trades at $168.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas NTRA's P/E ratio is -114.15. In terms of profitability, SERA's ROE is -0.51%, compared to NTRA's ROE of -0.18%. Regarding short-term risk, SERA is more volatile compared to NTRA. This indicates potentially higher risk in terms of short-term price fluctuations for SERA.
SERA vs WAT Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, WAT has a market cap of 20.8B. Regarding current trading prices, SERA is priced at $2.77, while WAT trades at $349.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas WAT's P/E ratio is 31.64. In terms of profitability, SERA's ROE is -0.51%, compared to WAT's ROE of +0.39%. Regarding short-term risk, SERA is more volatile compared to WAT. This indicates potentially higher risk in terms of short-term price fluctuations for SERA.
SERA vs DGX Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, DGX has a market cap of 20B. Regarding current trading prices, SERA is priced at $2.77, while DGX trades at $179.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas DGX's P/E ratio is 22.70. In terms of profitability, SERA's ROE is -0.51%, compared to DGX's ROE of +0.13%. Regarding short-term risk, SERA is more volatile compared to DGX. This indicates potentially higher risk in terms of short-term price fluctuations for SERA.
SERA vs ILMN Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, ILMN has a market cap of 15.1B. Regarding current trading prices, SERA is priced at $2.77, while ILMN trades at $95.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas ILMN's P/E ratio is -15.69. In terms of profitability, SERA's ROE is -0.51%, compared to ILMN's ROE of -0.46%. Regarding short-term risk, SERA is more volatile compared to ILMN. This indicates potentially higher risk in terms of short-term price fluctuations for SERA.
SERA vs PKI Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, PKI has a market cap of 14.5B. Regarding current trading prices, SERA is priced at $2.77, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas PKI's P/E ratio is 41.45. In terms of profitability, SERA's ROE is -0.51%, compared to PKI's ROE of +0.04%. Regarding short-term risk, SERA is more volatile compared to PKI. This indicates potentially higher risk in terms of short-term price fluctuations for SERA.
SERA vs ICLR Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, ICLR has a market cap of 11.7B. Regarding current trading prices, SERA is priced at $2.77, while ICLR trades at $145.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas ICLR's P/E ratio is 15.84. In terms of profitability, SERA's ROE is -0.51%, compared to ICLR's ROE of +0.08%. Regarding short-term risk, SERA is more volatile compared to ICLR. This indicates potentially higher risk in terms of short-term price fluctuations for SERA.
SERA vs RVTY Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, RVTY has a market cap of 11.4B. Regarding current trading prices, SERA is priced at $2.77, while RVTY trades at $96.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas RVTY's P/E ratio is 39.96. In terms of profitability, SERA's ROE is -0.51%, compared to RVTY's ROE of +0.04%. Regarding short-term risk, SERA is more volatile compared to RVTY. This indicates potentially higher risk in terms of short-term price fluctuations for SERA.
SERA vs TEM Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, TEM has a market cap of 10.7B. Regarding current trading prices, SERA is priced at $2.77, while TEM trades at $63.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas TEM's P/E ratio is -12.31. In terms of profitability, SERA's ROE is -0.51%, compared to TEM's ROE of -5.31%. Regarding short-term risk, SERA is more volatile compared to TEM. This indicates potentially higher risk in terms of short-term price fluctuations for SERA.
SERA vs QGEN Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, QGEN has a market cap of 10.4B. Regarding current trading prices, SERA is priced at $2.77, while QGEN trades at $48.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas QGEN's P/E ratio is 111.74. In terms of profitability, SERA's ROE is -0.51%, compared to QGEN's ROE of +0.03%. Regarding short-term risk, SERA is more volatile compared to QGEN. This indicates potentially higher risk in terms of short-term price fluctuations for SERA.
SERA vs EXAS Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, EXAS has a market cap of 10B. Regarding current trading prices, SERA is priced at $2.77, while EXAS trades at $53.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas EXAS's P/E ratio is -9.61. In terms of profitability, SERA's ROE is -0.51%, compared to EXAS's ROE of -0.36%. Regarding short-term risk, SERA is more volatile compared to EXAS. This indicates potentially higher risk in terms of short-term price fluctuations for SERA.
SERA vs MEDP Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, MEDP has a market cap of 9B. Regarding current trading prices, SERA is priced at $2.77, while MEDP trades at $313.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas MEDP's P/E ratio is 23.96. In terms of profitability, SERA's ROE is -0.51%, compared to MEDP's ROE of +0.54%. Regarding short-term risk, SERA is more volatile compared to MEDP. This indicates potentially higher risk in terms of short-term price fluctuations for SERA.
SERA vs CRL Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, CRL has a market cap of 7.5B. Regarding current trading prices, SERA is priced at $2.77, while CRL trades at $151.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas CRL's P/E ratio is -252.95. In terms of profitability, SERA's ROE is -0.51%, compared to CRL's ROE of -0.01%. Regarding short-term risk, SERA is more volatile compared to CRL. This indicates potentially higher risk in terms of short-term price fluctuations for SERA.
SERA vs GH Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, GH has a market cap of 6.4B. Regarding current trading prices, SERA is priced at $2.77, while GH trades at $52.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas GH's P/E ratio is -15.35. In terms of profitability, SERA's ROE is -0.51%, compared to GH's ROE of +3.69%. Regarding short-term risk, SERA is more volatile compared to GH. This indicates potentially higher risk in terms of short-term price fluctuations for SERA.
SERA vs SYNH Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, SYNH has a market cap of 4.5B. Regarding current trading prices, SERA is priced at $2.77, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas SYNH's P/E ratio is 61.40. In terms of profitability, SERA's ROE is -0.51%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, SERA is more volatile compared to SYNH. This indicates potentially higher risk in terms of short-term price fluctuations for SERA.
SERA vs RDNT Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, RDNT has a market cap of 4.3B. Regarding current trading prices, SERA is priced at $2.77, while RDNT trades at $56.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas RDNT's P/E ratio is -132.35. In terms of profitability, SERA's ROE is -0.51%, compared to RDNT's ROE of +0.03%. Regarding short-term risk, SERA is more volatile compared to RDNT. This indicates potentially higher risk in terms of short-term price fluctuations for SERA.
SERA vs OLK Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, SERA is priced at $2.77, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas OLK's P/E ratio is -96.59. In terms of profitability, SERA's ROE is -0.51%, compared to OLK's ROE of -0.05%. Regarding short-term risk, SERA is more volatile compared to OLK. This indicates potentially higher risk in terms of short-term price fluctuations for SERA.
SERA vs SHC Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, SHC has a market cap of 3.2B. Regarding current trading prices, SERA is priced at $2.77, while SHC trades at $11.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas SHC's P/E ratio is 123.56. In terms of profitability, SERA's ROE is -0.51%, compared to SHC's ROE of +0.06%. Regarding short-term risk, SERA is more volatile compared to SHC. This indicates potentially higher risk in terms of short-term price fluctuations for SERA.
SERA vs TWST Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, TWST has a market cap of 2.2B. Regarding current trading prices, SERA is priced at $2.77, while TWST trades at $36.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas TWST's P/E ratio is -11.32. In terms of profitability, SERA's ROE is -0.51%, compared to TWST's ROE of -0.41%. Regarding short-term risk, SERA is more volatile compared to TWST. This indicates potentially higher risk in terms of short-term price fluctuations for SERA.
SERA vs GRAL Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, GRAL has a market cap of 1.8B. Regarding current trading prices, SERA is priced at $2.77, while GRAL trades at $51.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas GRAL's P/E ratio is -0.86. In terms of profitability, SERA's ROE is -0.51%, compared to GRAL's ROE of -0.75%. Regarding short-term risk, SERA is more volatile compared to GRAL. This indicates potentially higher risk in terms of short-term price fluctuations for SERA.
SERA vs VIVO Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, VIVO has a market cap of 1.5B. Regarding current trading prices, SERA is priced at $2.77, while VIVO trades at $33.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas VIVO's P/E ratio is 21.09. In terms of profitability, SERA's ROE is -0.51%, compared to VIVO's ROE of +0.12%. Regarding short-term risk, SERA is more volatile compared to VIVO. This indicates potentially higher risk in terms of short-term price fluctuations for SERA.
SERA vs CDNA Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, CDNA has a market cap of 1.1B. Regarding current trading prices, SERA is priced at $2.77, while CDNA trades at $19.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas CDNA's P/E ratio is 17.45. In terms of profitability, SERA's ROE is -0.51%, compared to CDNA's ROE of +0.18%. Regarding short-term risk, SERA is more volatile compared to CDNA. This indicates potentially higher risk in terms of short-term price fluctuations for SERA.
SERA vs OPK Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, OPK has a market cap of 1B. Regarding current trading prices, SERA is priced at $2.77, while OPK trades at $1.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas OPK's P/E ratio is -22.00. In terms of profitability, SERA's ROE is -0.51%, compared to OPK's ROE of -0.03%. Regarding short-term risk, SERA is more volatile compared to OPK. This indicates potentially higher risk in terms of short-term price fluctuations for SERA.
SERA vs NEOG Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, NEOG has a market cap of 1B. Regarding current trading prices, SERA is priced at $2.77, while NEOG trades at $4.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas NEOG's P/E ratio is -2.14. In terms of profitability, SERA's ROE is -0.51%, compared to NEOG's ROE of -0.17%. Regarding short-term risk, SERA is more volatile compared to NEOG. This indicates potentially higher risk in terms of short-term price fluctuations for SERA.
SERA vs FLGT Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, FLGT has a market cap of 605.2M. Regarding current trading prices, SERA is priced at $2.77, while FLGT trades at $19.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas FLGT's P/E ratio is -14.95. In terms of profitability, SERA's ROE is -0.51%, compared to FLGT's ROE of -0.04%. Regarding short-term risk, SERA is more volatile compared to FLGT. This indicates potentially higher risk in terms of short-term price fluctuations for SERA.
SERA vs CSTL Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, CSTL has a market cap of 589.6M. Regarding current trading prices, SERA is priced at $2.77, while CSTL trades at $20.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas CSTL's P/E ratio is -107.47. In terms of profitability, SERA's ROE is -0.51%, compared to CSTL's ROE of -0.01%. Regarding short-term risk, SERA is more volatile compared to CSTL. This indicates potentially higher risk in terms of short-term price fluctuations for SERA.
SERA vs PSNL Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, PSNL has a market cap of 579.4M. Regarding current trading prices, SERA is priced at $2.77, while PSNL trades at $6.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas PSNL's P/E ratio is -5.09. In terms of profitability, SERA's ROE is -0.51%, compared to PSNL's ROE of -0.49%. Regarding short-term risk, SERA is more volatile compared to PSNL. This indicates potentially higher risk in terms of short-term price fluctuations for SERA.
SERA vs GRALV Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, GRALV has a market cap of 579.4M. Regarding current trading prices, SERA is priced at $2.77, while GRALV trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas GRALV's P/E ratio is N/A. In terms of profitability, SERA's ROE is -0.51%, compared to GRALV's ROE of N/A. Regarding short-term risk, SERA is more volatile compared to GRALV. This indicates potentially higher risk in terms of short-term price fluctuations for SERA.
SERA vs MYGN Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, MYGN has a market cap of 489.5M. Regarding current trading prices, SERA is priced at $2.77, while MYGN trades at $5.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas MYGN's P/E ratio is -4.74. In terms of profitability, SERA's ROE is -0.51%, compared to MYGN's ROE of -0.14%. Regarding short-term risk, SERA is more volatile compared to MYGN. This indicates potentially higher risk in terms of short-term price fluctuations for SERA.
SERA vs LAB Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, LAB has a market cap of 455.8M. Regarding current trading prices, SERA is priced at $2.77, while LAB trades at $1.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas LAB's P/E ratio is -3.75. In terms of profitability, SERA's ROE is -0.51%, compared to LAB's ROE of -0.28%. Regarding short-term risk, SERA is more volatile compared to LAB. This indicates potentially higher risk in terms of short-term price fluctuations for SERA.
SERA vs CO Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, CO has a market cap of 400.1M. Regarding current trading prices, SERA is priced at $2.77, while CO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas CO's P/E ratio is 5.06. In terms of profitability, SERA's ROE is -0.51%, compared to CO's ROE of +0.11%. Regarding short-term risk, SERA is less volatile compared to CO. This indicates potentially lower risk in terms of short-term price fluctuations for SERA.
SERA vs FLDM Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, SERA is priced at $2.77, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas FLDM's P/E ratio is -4.74. In terms of profitability, SERA's ROE is -0.51%, compared to FLDM's ROE of -0.28%. Regarding short-term risk, SERA is more volatile compared to FLDM. This indicates potentially higher risk in terms of short-term price fluctuations for SERA.
SERA vs STIM Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, STIM has a market cap of 229.7M. Regarding current trading prices, SERA is priced at $2.77, while STIM trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas STIM's P/E ratio is -2.64. In terms of profitability, SERA's ROE is -0.51%, compared to STIM's ROE of -2.09%. Regarding short-term risk, SERA is more volatile compared to STIM. This indicates potentially higher risk in terms of short-term price fluctuations for SERA.
SERA vs NEO Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, NEO has a market cap of 188.2M. Regarding current trading prices, SERA is priced at $2.77, while NEO trades at $7.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas NEO's P/E ratio is -11.98. In terms of profitability, SERA's ROE is -0.51%, compared to NEO's ROE of -0.09%. Regarding short-term risk, SERA is more volatile compared to NEO. This indicates potentially higher risk in terms of short-term price fluctuations for SERA.
SERA vs ACRS Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, ACRS has a market cap of 153.8M. Regarding current trading prices, SERA is priced at $2.77, while ACRS trades at $1.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas ACRS's P/E ratio is -0.89. In terms of profitability, SERA's ROE is -0.51%, compared to ACRS's ROE of -0.92%. Regarding short-term risk, SERA is more volatile compared to ACRS. This indicates potentially higher risk in terms of short-term price fluctuations for SERA.
SERA vs XGN Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, XGN has a market cap of 152.6M. Regarding current trading prices, SERA is priced at $2.77, while XGN trades at $6.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas XGN's P/E ratio is -8.31. In terms of profitability, SERA's ROE is -0.51%, compared to XGN's ROE of -1.34%. Regarding short-term risk, SERA is more volatile compared to XGN. This indicates potentially higher risk in terms of short-term price fluctuations for SERA.
SERA vs PRENW Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, PRENW has a market cap of 151.7M. Regarding current trading prices, SERA is priced at $2.77, while PRENW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas PRENW's P/E ratio is N/A. In terms of profitability, SERA's ROE is -0.51%, compared to PRENW's ROE of -0.28%. Regarding short-term risk, SERA is less volatile compared to PRENW. This indicates potentially lower risk in terms of short-term price fluctuations for SERA.
SERA vs GTH Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, GTH has a market cap of 127.3M. Regarding current trading prices, SERA is priced at $2.77, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas GTH's P/E ratio is -1.11. In terms of profitability, SERA's ROE is -0.51%, compared to GTH's ROE of -1.01%. Regarding short-term risk, SERA is more volatile compared to GTH. This indicates potentially higher risk in terms of short-term price fluctuations for SERA.
SERA vs ATLN Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, ATLN has a market cap of 118.5M. Regarding current trading prices, SERA is priced at $2.77, while ATLN trades at $2.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas ATLN's P/E ratio is -0.55. In terms of profitability, SERA's ROE is -0.51%, compared to ATLN's ROE of -19.68%. Regarding short-term risk, SERA is more volatile compared to ATLN. This indicates potentially higher risk in terms of short-term price fluctuations for SERA.
SERA vs GENE Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, GENE has a market cap of 111.2M. Regarding current trading prices, SERA is priced at $2.77, while GENE trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas GENE's P/E ratio is -38.25. In terms of profitability, SERA's ROE is -0.51%, compared to GENE's ROE of -3.62%. Regarding short-term risk, SERA is more volatile compared to GENE. This indicates potentially higher risk in terms of short-term price fluctuations for SERA.
SERA vs PRE Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, PRE has a market cap of 111M. Regarding current trading prices, SERA is priced at $2.77, while PRE trades at $8.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas PRE's P/E ratio is -2.23. In terms of profitability, SERA's ROE is -0.51%, compared to PRE's ROE of -0.28%. Regarding short-term risk, SERA is more volatile compared to PRE. This indicates potentially higher risk in terms of short-term price fluctuations for SERA.
SERA vs MDXH Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, MDXH has a market cap of 109.4M. Regarding current trading prices, SERA is priced at $2.77, while MDXH trades at $2.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas MDXH's P/E ratio is -2.12. In terms of profitability, SERA's ROE is -0.51%, compared to MDXH's ROE of -5.35%. Regarding short-term risk, SERA is more volatile compared to MDXH. This indicates potentially higher risk in terms of short-term price fluctuations for SERA.
SERA vs VNRX Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, VNRX has a market cap of 79M. Regarding current trading prices, SERA is priced at $2.77, while VNRX trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas VNRX's P/E ratio is -2.84. In terms of profitability, SERA's ROE is -0.51%, compared to VNRX's ROE of +1.08%. Regarding short-term risk, SERA is more volatile compared to VNRX. This indicates potentially higher risk in terms of short-term price fluctuations for SERA.
SERA vs NOTV Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, NOTV has a market cap of 62.5M. Regarding current trading prices, SERA is priced at $2.77, while NOTV trades at $1.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas NOTV's P/E ratio is -0.58. In terms of profitability, SERA's ROE is -0.51%, compared to NOTV's ROE of -0.51%. Regarding short-term risk, SERA is more volatile compared to NOTV. This indicates potentially higher risk in terms of short-term price fluctuations for SERA.
SERA vs OPGN Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, OPGN has a market cap of 42.3M. Regarding current trading prices, SERA is priced at $2.77, while OPGN trades at $4.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas OPGN's P/E ratio is -0.27. In terms of profitability, SERA's ROE is -0.51%, compared to OPGN's ROE of +1.20%. Regarding short-term risk, SERA is more volatile compared to OPGN. This indicates potentially higher risk in terms of short-term price fluctuations for SERA.
SERA vs BDSX Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, BDSX has a market cap of 41.4M. Regarding current trading prices, SERA is priced at $2.77, while BDSX trades at $0.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas BDSX's P/E ratio is -1.05. In terms of profitability, SERA's ROE is -0.51%, compared to BDSX's ROE of -1.68%. Regarding short-term risk, SERA is more volatile compared to BDSX. This indicates potentially higher risk in terms of short-term price fluctuations for SERA.
SERA vs DRIO Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, DRIO has a market cap of 29.8M. Regarding current trading prices, SERA is priced at $2.77, while DRIO trades at $0.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas DRIO's P/E ratio is -1.22. In terms of profitability, SERA's ROE is -0.51%, compared to DRIO's ROE of -0.17%. Regarding short-term risk, SERA is more volatile compared to DRIO. This indicates potentially higher risk in terms of short-term price fluctuations for SERA.
SERA vs STRRP Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, STRRP has a market cap of 28.8M. Regarding current trading prices, SERA is priced at $2.77, while STRRP trades at $8.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas STRRP's P/E ratio is -4.50. In terms of profitability, SERA's ROE is -0.51%, compared to STRRP's ROE of -0.24%. Regarding short-term risk, SERA is more volatile compared to STRRP. This indicates potentially higher risk in terms of short-term price fluctuations for SERA.
SERA vs AKU Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, SERA is priced at $2.77, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas AKU's P/E ratio is -0.13. In terms of profitability, SERA's ROE is -0.51%, compared to AKU's ROE of -5.32%. Regarding short-term risk, SERA is more volatile compared to AKU. This indicates potentially higher risk in terms of short-term price fluctuations for SERA.
SERA vs PRPO Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, PRPO has a market cap of 16.9M. Regarding current trading prices, SERA is priced at $2.77, while PRPO trades at $11.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas PRPO's P/E ratio is -5.44. In terms of profitability, SERA's ROE is -0.51%, compared to PRPO's ROE of -0.26%. Regarding short-term risk, SERA is more volatile compared to PRPO. This indicates potentially higher risk in terms of short-term price fluctuations for SERA.
SERA vs CEMI Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, CEMI has a market cap of 16.7M. Regarding current trading prices, SERA is priced at $2.77, while CEMI trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas CEMI's P/E ratio is -0.63. In terms of profitability, SERA's ROE is -0.51%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, SERA is more volatile compared to CEMI. This indicates potentially higher risk in terms of short-term price fluctuations for SERA.
SERA vs ENZ Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, ENZ has a market cap of 16.4M. Regarding current trading prices, SERA is priced at $2.77, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas ENZ's P/E ratio is -2.24. In terms of profitability, SERA's ROE is -0.51%, compared to ENZ's ROE of -0.39%. Regarding short-term risk, SERA is more volatile compared to ENZ. This indicates potentially higher risk in terms of short-term price fluctuations for SERA.
SERA vs PMD Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, PMD has a market cap of 15.7M. Regarding current trading prices, SERA is priced at $2.77, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas PMD's P/E ratio is -5.24. In terms of profitability, SERA's ROE is -0.51%, compared to PMD's ROE of -0.33%. Regarding short-term risk, SERA is more volatile compared to PMD. This indicates potentially higher risk in terms of short-term price fluctuations for SERA.
SERA vs ADVB Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, ADVB has a market cap of 15.1M. Regarding current trading prices, SERA is priced at $2.77, while ADVB trades at $0.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas ADVB's P/E ratio is -4.37. In terms of profitability, SERA's ROE is -0.51%, compared to ADVB's ROE of -1.86%. Regarding short-term risk, SERA is more volatile compared to ADVB. This indicates potentially higher risk in terms of short-term price fluctuations for SERA.
SERA vs ME Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, ME has a market cap of 13.3M. Regarding current trading prices, SERA is priced at $2.77, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas ME's P/E ratio is -0.03. In terms of profitability, SERA's ROE is -0.51%, compared to ME's ROE of -3.10%. Regarding short-term risk, SERA is more volatile compared to ME. This indicates potentially higher risk in terms of short-term price fluctuations for SERA.
SERA vs TRIB Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, TRIB has a market cap of 12.1M. Regarding current trading prices, SERA is priced at $2.77, while TRIB trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas TRIB's P/E ratio is -0.36. In terms of profitability, SERA's ROE is -0.51%, compared to TRIB's ROE of +1.12%. Regarding short-term risk, SERA is more volatile compared to TRIB. This indicates potentially higher risk in terms of short-term price fluctuations for SERA.
SERA vs INBS Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, INBS has a market cap of 11.9M. Regarding current trading prices, SERA is priced at $2.77, while INBS trades at $1.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas INBS's P/E ratio is -1.29. In terms of profitability, SERA's ROE is -0.51%, compared to INBS's ROE of -1.72%. Regarding short-term risk, SERA is more volatile compared to INBS. This indicates potentially higher risk in terms of short-term price fluctuations for SERA.
SERA vs BNGO Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, BNGO has a market cap of 11M. Regarding current trading prices, SERA is priced at $2.77, while BNGO trades at $3.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas BNGO's P/E ratio is -0.06. In terms of profitability, SERA's ROE is -0.51%, compared to BNGO's ROE of -1.57%. Regarding short-term risk, SERA is more volatile compared to BNGO. This indicates potentially higher risk in terms of short-term price fluctuations for SERA.
SERA vs CNTG Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, CNTG has a market cap of 9.4M. Regarding current trading prices, SERA is priced at $2.77, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas CNTG's P/E ratio is -0.23. In terms of profitability, SERA's ROE is -0.51%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, SERA is more volatile compared to CNTG. This indicates potentially higher risk in terms of short-term price fluctuations for SERA.
SERA vs BIAF Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, BIAF has a market cap of 8.2M. Regarding current trading prices, SERA is priced at $2.77, while BIAF trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas BIAF's P/E ratio is -0.40. In terms of profitability, SERA's ROE is -0.51%, compared to BIAF's ROE of -3.68%. Regarding short-term risk, SERA is more volatile compared to BIAF. This indicates potentially higher risk in terms of short-term price fluctuations for SERA.
SERA vs STRR Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, STRR has a market cap of 6.4M. Regarding current trading prices, SERA is priced at $2.77, while STRR trades at $2.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas STRR's P/E ratio is -0.67. In terms of profitability, SERA's ROE is -0.51%, compared to STRR's ROE of -0.24%. Regarding short-term risk, SERA is more volatile compared to STRR. This indicates potentially higher risk in terms of short-term price fluctuations for SERA.
SERA vs BIAFW Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, BIAFW has a market cap of 6.2M. Regarding current trading prices, SERA is priced at $2.77, while BIAFW trades at $0.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas BIAFW's P/E ratio is N/A. In terms of profitability, SERA's ROE is -0.51%, compared to BIAFW's ROE of -3.68%. Regarding short-term risk, SERA is more volatile compared to BIAFW. This indicates potentially higher risk in terms of short-term price fluctuations for SERA.
SERA vs BGLC Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, BGLC has a market cap of 5.6M. Regarding current trading prices, SERA is priced at $2.77, while BGLC trades at $3.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas BGLC's P/E ratio is -2.63. In terms of profitability, SERA's ROE is -0.51%, compared to BGLC's ROE of -0.24%. Regarding short-term risk, SERA is more volatile compared to BGLC. This indicates potentially higher risk in terms of short-term price fluctuations for SERA.
SERA vs NVTA Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, NVTA has a market cap of 5.4M. Regarding current trading prices, SERA is priced at $2.77, while NVTA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas NVTA's P/E ratio is -0.00. In terms of profitability, SERA's ROE is -0.51%, compared to NVTA's ROE of -2.02%. Regarding short-term risk, SERA is less volatile compared to NVTA. This indicates potentially lower risk in terms of short-term price fluctuations for SERA.
SERA vs MYNZ Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, MYNZ has a market cap of 5.4M. Regarding current trading prices, SERA is priced at $2.77, while MYNZ trades at $1.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas MYNZ's P/E ratio is -0.06. In terms of profitability, SERA's ROE is -0.51%, compared to MYNZ's ROE of -22.70%. Regarding short-term risk, SERA is more volatile compared to MYNZ. This indicates potentially higher risk in terms of short-term price fluctuations for SERA.
SERA vs LMDX Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, SERA is priced at $2.77, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas LMDX's P/E ratio is -0.01. In terms of profitability, SERA's ROE is -0.51%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, SERA is less volatile compared to LMDX. This indicates potentially lower risk in terms of short-term price fluctuations for SERA.
SERA vs LMDXW Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, LMDXW has a market cap of 5.1M. Regarding current trading prices, SERA is priced at $2.77, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas LMDXW's P/E ratio is N/A. In terms of profitability, SERA's ROE is -0.51%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, SERA is less volatile compared to LMDXW. This indicates potentially lower risk in terms of short-term price fluctuations for SERA.
SERA vs CHEK Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, CHEK has a market cap of 4.4M. Regarding current trading prices, SERA is priced at $2.77, while CHEK trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas CHEK's P/E ratio is -0.36. In terms of profitability, SERA's ROE is -0.51%, compared to CHEK's ROE of -0.52%. Regarding short-term risk, SERA is more volatile compared to CHEK. This indicates potentially higher risk in terms of short-term price fluctuations for SERA.
SERA vs TTOO Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, TTOO has a market cap of 4.3M. Regarding current trading prices, SERA is priced at $2.77, while TTOO trades at $0.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas TTOO's P/E ratio is -5.17. In terms of profitability, SERA's ROE is -0.51%, compared to TTOO's ROE of +2.06%. Regarding short-term risk, SERA is more volatile compared to TTOO. This indicates potentially higher risk in terms of short-term price fluctuations for SERA.
SERA vs BNR Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, BNR has a market cap of 3.4M. Regarding current trading prices, SERA is priced at $2.77, while BNR trades at $3.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas BNR's P/E ratio is -0.99. In terms of profitability, SERA's ROE is -0.51%, compared to BNR's ROE of -0.39%. Regarding short-term risk, SERA is more volatile compared to BNR. This indicates potentially higher risk in terms of short-term price fluctuations for SERA.
SERA vs DMTK Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, SERA is priced at $2.77, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas DMTK's P/E ratio is -0.04. In terms of profitability, SERA's ROE is -0.51%, compared to DMTK's ROE of -0.80%. Regarding short-term risk, SERA is more volatile compared to DMTK. This indicates potentially higher risk in terms of short-term price fluctuations for SERA.
SERA vs AWH Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, AWH has a market cap of 2.9M. Regarding current trading prices, SERA is priced at $2.77, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas AWH's P/E ratio is -0.09. In terms of profitability, SERA's ROE is -0.51%, compared to AWH's ROE of +4.66%. Regarding short-term risk, SERA is more volatile compared to AWH. This indicates potentially higher risk in terms of short-term price fluctuations for SERA.
SERA vs APDN Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, APDN has a market cap of 2.6M. Regarding current trading prices, SERA is priced at $2.77, while APDN trades at $5.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas APDN's P/E ratio is N/A. In terms of profitability, SERA's ROE is -0.51%, compared to APDN's ROE of -2.81%. Regarding short-term risk, SERA is more volatile compared to APDN. This indicates potentially higher risk in terms of short-term price fluctuations for SERA.
SERA vs NDRA Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, NDRA has a market cap of 2.6M. Regarding current trading prices, SERA is priced at $2.77, while NDRA trades at $3.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas NDRA's P/E ratio is 0.01. In terms of profitability, SERA's ROE is -0.51%, compared to NDRA's ROE of -1.96%. Regarding short-term risk, SERA is more volatile compared to NDRA. This indicates potentially higher risk in terms of short-term price fluctuations for SERA.
SERA vs SQL Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, SERA is priced at $2.77, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas SQL's P/E ratio is -0.40. In terms of profitability, SERA's ROE is -0.51%, compared to SQL's ROE of +10.89%. Regarding short-term risk, SERA is more volatile compared to SQL. This indicates potentially higher risk in terms of short-term price fluctuations for SERA.
SERA vs ISPC Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, ISPC has a market cap of 2.4M. Regarding current trading prices, SERA is priced at $2.77, while ISPC trades at $0.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas ISPC's P/E ratio is -0.08. In terms of profitability, SERA's ROE is -0.51%, compared to ISPC's ROE of -2.85%. Regarding short-term risk, SERA is more volatile compared to ISPC. This indicates potentially higher risk in terms of short-term price fluctuations for SERA.
SERA vs HTGM Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, HTGM has a market cap of 1.1M. Regarding current trading prices, SERA is priced at $2.77, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas HTGM's P/E ratio is -0.03. In terms of profitability, SERA's ROE is -0.51%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, SERA is more volatile compared to HTGM. This indicates potentially higher risk in terms of short-term price fluctuations for SERA.
SERA vs BIOC Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, BIOC has a market cap of 450.8K. Regarding current trading prices, SERA is priced at $2.77, while BIOC trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas BIOC's P/E ratio is -0.01. In terms of profitability, SERA's ROE is -0.51%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, SERA is more volatile compared to BIOC. This indicates potentially higher risk in terms of short-term price fluctuations for SERA.
SERA vs SQLLW Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, SQLLW has a market cap of 117.9K. Regarding current trading prices, SERA is priced at $2.77, while SQLLW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas SQLLW's P/E ratio is -0.01. In terms of profitability, SERA's ROE is -0.51%, compared to SQLLW's ROE of -19.68%. Regarding short-term risk, SERA is more volatile compared to SQLLW. This indicates potentially higher risk in terms of short-term price fluctuations for SERA.
SERA vs OCDX Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, OCDX has a market cap of 0. Regarding current trading prices, SERA is priced at $2.77, while OCDX trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas OCDX's P/E ratio is -42.28. In terms of profitability, SERA's ROE is -0.51%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, SERA is more volatile compared to OCDX. This indicates potentially higher risk in terms of short-term price fluctuations for SERA.
SERA vs DHR-PA Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, SERA is priced at $2.77, while DHR-PA trades at $1,841.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, SERA's ROE is -0.51%, compared to DHR-PA's ROE of +0.07%. Regarding short-term risk, SERA is more volatile compared to DHR-PA. This indicates potentially higher risk in terms of short-term price fluctuations for SERA.
SERA vs MEUSW Comparison
SERA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 101.7M. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, SERA is priced at $2.77, while MEUSW trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -2.95, whereas MEUSW's P/E ratio is N/A. In terms of profitability, SERA's ROE is -0.51%, compared to MEUSW's ROE of -3.10%. Regarding short-term risk, SERA is more volatile compared to MEUSW. This indicates potentially higher risk in terms of short-term price fluctuations for SERA.